Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2 Positive Breast Cancer × pyrotinib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 HER2-positive Breast Cancer 4 Salivary Gland Neoplasms 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2 Positive Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Invasive 1 Breast Cancer Female 1 Advanced Digestive System Tumor 1 Advanced Breast Cancer 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06958627 2025-05-06

any

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3 Recruiting

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡